About Me
I am a radiologist and nuclear medicine specialist with a major interest in cancer imaging and treatment. My goal is to provide anatomic and molecular imaging that will guide patient care and improve treatment outcomes. Another major interest that I have is radiotheranostics, where we utilize targeted molecular probes (radiotracers) for imaging potential tumor targets with PET/CT or SPECT/CT. We then treat the tumors with similar molecular probes attached to a therapeutic radioisotope.
- Professor of Radiology, Radiology, Nuclear Medicine 2019
- Professor in Medicine, Medicine, Medical Oncology 2020
- Member of the Duke Cancer Institute, Duke Cancer Institute 2018
Call for an Appointment
Training and Education
Clinical Focus and Research
My major clinical interests are in gastrointestinal and genitourinary oncology and utilizing molecular imaging as a biomarker. Imaging can help determine which patients are likely to respond to targeted therapy or can be used to determine a response to therapy early in the course of treatment.
- Positron Emission Tomography using 64Cu-SAR-bisPSMA in participants with high-risk prostate cancer prior to radical prostatectomy: A prospective, single-arm, multi-center, blinded-review, Phase 3 diagnostic performance study awarded by Clarity Pharmaceuticals Pty Ltd (Clarity Pharmaceuticals) 2024 - 2027
- ECOG-ACRIN Operations Center - Clinical Trials awarded by ECOG-ACRIN Medical Research Foundation Inc. 2019 - 2026
- Ma, Jinli, Junan Zhang, Sumin Zhou, Jessica L. Hubbs, Rodney J. Foltz, Donna R. Hollis, Kim L. Light, Terence Z. Wong, Christopher R. Kelsey, and Lawrence B. Marks. “Regional lung density changes after radiation therapy for tumors in and around thorax.” Int J Radiat Oncol Biol Phys 76, no. 1 (January 1, 2010): 116–22. https://doi.org/10.1016/j.ijrobp.2009.01.025.
- Kimura, Masaki, Matvey Tsivian, Vladimir Mouraviev, Janice M. Mayes, Marva M. Price, Michael C. Bannister, John F. Madden, Terence Z. Wong, and Thomas J. Polascik. “Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.” Int J Urol 16, no. 12 (December 2009): 971–75. https://doi.org/10.1111/j.1442-2042.2009.02413.x.
- Craciunescu, Oana I., Paul R. Stauffer, Brian J. Soher, Cory R. Wyatt, Omar Arabe, Paolo Maccarini, Shiva K. Das, et al. “Accuracy of real time noninvasive temperature measurements using magnetic resonance thermal imaging in patients treated for high grade extremity soft tissue sarcomas.” Med Phys 36, no. 11 (November 2009): 4848–58. https://doi.org/10.1118/1.3227506.
- Wong, T. Z. “Microwave hyperthermia for benign prostatic hyperplasia and adenocarcinoma of the prostate.” In Hyperthermia And Oncology: Volume 3: Interstitial Hyperthermia: Physics, Biology and Clinical Aspects, 3:245–58, 2023. https://doi.org/10.1201/9780429070631-10.
- Oldan, J. D., J. Hoang, and T. Z. Wong. “Imaging modalities in the diagnosis of recurrent or metastatic thyroid cancer.” In Management of Differentiated Thyroid Cancer, 233–54, 2017. https://doi.org/10.1007/978-3-319-54493-9_19.
- Wong, T. Z., A. H. Khandani, and A. Sheikh. “Nuclear Medicine.” In Clinical Radiation Oncology, 206–16, 2015. https://doi.org/10.1016/B978-0-323-24098-7.00011-3.
- Vapiwala, Neha, Yu-Hui Chen, Steve Y. Cho, Fenghai Duan, Christos Kyriakopoulos, Alicia K. Morgans, Daniel H. Shevrin, et al. “Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
- Vapiwala, Neha, Yu-Hui Chen, Steve Y. Cho, Fenghai Duan, Christos Kyriakopoulos, Alicia K. Morgans, Daniel H. Shevrin, et al. “Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
- Vijayvergia, Namrata, Elizabeth A. Handorf, Pamela L. Kunz, Emel Alkim, Lauren M. B. Burke, Paul J. Catalano, Noah Graham, et al. “Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- Lantheus / Progenics pharmaceuticals
- Novartis pharmaceuticals
- telix pharmaceuticals